Skip to main content
Top
Published in: Journal of General Internal Medicine 5/2020

01-05-2020 | Buprenorphine | Original Research

Racial/Ethnic Differences in the Medical Treatment of Opioid Use Disorders Within the VA Healthcare System Following Non-Fatal Opioid Overdose

Authors: Utibe R. Essien, MD, MPH, Florentina E. Sileanu, MS, Xinhua Zhao, PhD, Jane M. Liebschutz, MD, MPH, Carolyn T. Thorpe, PhD, Chester B. Good, MD, Maria K. Mor, PhD, Thomas R. Radomski, MD, MS, Leslie R. M. Hausmann, PhD, Michael J. Fine, MD, MSc, Walid F. Gellad, MD, MPH

Published in: Journal of General Internal Medicine | Issue 5/2020

Login to get access

Abstract

Background

After non-fatal opioid overdoses, opioid prescribing patterns are often unchanged and the use of medications for opioid use disorder (MOUDs) remains low. Whether such prescribing differs by race/ethnicity remains unknown.

Objective

To assess the association of race/ethnicity with the prescribing of opioids and MOUDs after a non-fatal opioid overdose.

Design

Retrospective cohort study.

Participants

Patients prescribed ≥ 1 opioid from July 1, 2010, to September 30, 2015, with a non-fatal opioid overdose in the Veterans Health Administration (VA).

Main Measures

Primary outcomes were the proportion of patients prescribed: (1) any opioid during the 30 days before and after overdose and (2) MOUDs within 30 days after overdose by race and ethnicity. We conducted difference-in-difference analyses using multivariable regression to assess whether the change in opioid prescribing from before to after overdose differed by race/ethnicity. We also used multivariable regression to test whether MOUD prescribing after overdose differed by race/ethnicity.

Key Results

Among 16,210 patients with a non-fatal opioid overdose (81.2% were white, 14.3% black, and 4.5% Hispanic), 10,745 (66.3%) patients received an opioid prescription (67.1% white, 61.7% black, and 65.9% Hispanic; p < 0.01) before overdose. After overdose, the frequency of receiving opioids was reduced by 18.3, 16.4, and 20.6 percentage points in whites, blacks, and Hispanics, respectively, with no significant difference-in-difference in opioid prescribing by race/ethnicity (p = 0.23). After overdose, 526 (3.2%) patients received MOUDs (2.9% white, 4.6% black, and 5.5% Hispanic; p < 0.01). Blacks (adjusted OR (aOR) 1.6; 95% CI 1.2, 1.9) and Hispanics (aOR 1.8; 95% CI 1.2, 2.6) had significantly larger odds of receiving MOUDs than white patients.

Conclusions

In a national cohort of patients with non-fatal opioid overdose in VA, there were no racial/ethnic differences in changes in opioid prescribing after overdose. Although blacks and Hispanics were more likely than white patients to receive MOUDs in the 30 days after overdose, less than 4% of all groups received such therapy.
Literature
14.
go back to reference Green CA, Perrin NA, Janoff SL, Campbell CI, Chilcoat HD, Coplan PM. Assessing the accuracy of opioid overdose and poisoning codes in diagnostic information from electronic health records, claims data, and death records. Pharmacoepidemiol Drug Saf. 2017. https://doi.org/10.1002/pds.4157 Green CA, Perrin NA, Janoff SL, Campbell CI, Chilcoat HD, Coplan PM. Assessing the accuracy of opioid overdose and poisoning codes in diagnostic information from electronic health records, claims data, and death records. Pharmacoepidemiol Drug Saf. 2017. https://​doi.​org/​10.​1002/​pds.​4157
22.
go back to reference The Management of Substance Use DIsorders. VA / DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Assessment. 2015. The Management of Substance Use DIsorders. VA / DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Assessment. 2015.
Metadata
Title
Racial/Ethnic Differences in the Medical Treatment of Opioid Use Disorders Within the VA Healthcare System Following Non-Fatal Opioid Overdose
Authors
Utibe R. Essien, MD, MPH
Florentina E. Sileanu, MS
Xinhua Zhao, PhD
Jane M. Liebschutz, MD, MPH
Carolyn T. Thorpe, PhD
Chester B. Good, MD
Maria K. Mor, PhD
Thomas R. Radomski, MD, MS
Leslie R. M. Hausmann, PhD
Michael J. Fine, MD, MSc
Walid F. Gellad, MD, MPH
Publication date
01-05-2020
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 5/2020
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-020-05645-0

Other articles of this Issue 5/2020

Journal of General Internal Medicine 5/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.